真实世界实践中慢性肢体威胁性缺血的血运重建:腔内治疗与旁路手术比较
基于血管质量倡议-医保链接数据库,对2010-2019年首次下肢血运重建的慢性肢体威胁性缺血患者行倾向性评分匹配,比较腔内治疗与自体大隐静脉旁路或人工血管旁路的结局。匹配后腔内治疗对比自体静脉旁路在4年内死亡、截肢及截肢/死亡风险均更高;对比人工血管旁路在2年内死亡风险更高,截肢及截肢/死亡无显著差异。
要点
- 匹配后腔内治疗对比自体大隐静脉旁路:死亡HR 1.34、截肢HR 1.30、截肢/死亡HR 1.32,均P<.001,随访至4年。
- 匹配后腔内治疗对比人工血管旁路:2年内死亡HR 1.11(95%CI 1.00-1.22,P=.042),截肢及截肢/死亡无显著差异。
- 真实世界多机构数据证实自体大隐静脉旁路优于腔内治疗,与BEST-CLI试验观察一致。
核心结论
- 在真实世界多机构医保链接倾向性评分匹配分析中,自体大隐静脉旁路在总生存、免于截肢及无截肢生存方面至4年优于腔内治疗。
- 人工血管旁路在总生存方面至2年优于腔内治疗。
- 本研究证实了BEST-CLI试验中观察到的自体大隐静脉旁路优于腔内治疗。
研究设计与样本
- 使用血管质量倡议-医保链接数据库查询2010-2019年首次下肢血运重建的慢性肢体威胁性缺血患者。
- 共查询三个队列:自体大隐静脉旁路(N=5279,14.7%)、人工血管旁路(N=2778,7.7%)、腔内治疗(N=27977,77.6%)。
- 行两组一对一倾向性评分匹配:腔内治疗对比自体大隐静脉旁路匹配4705对,腔内治疗对比人工血管旁路匹配2583对。
- 主要结局为无截肢生存,次要结局为免于截肢和总生存。
主要发现
- 腔内治疗对比自体大隐静脉旁路匹配队列:死亡HR=1.34(95%CI 1.25-1.43,P<.001),截肢HR=1.30(95%CI 1.17-1.44,P<.001),截肢/死亡HR=1.32(95%CI 1.24-1.40,P<.001),随访至4年。
- 腔内治疗对比人工血管旁路匹配队列:死亡HR=1.11(95%CI 1.00-1.22,P=.042),随访至2年;截肢及截肢/死亡无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The recent Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) study showed that bypass was superior to endovascular therapy (ET) in patients with chronic limb-threatening ischemia (CLTI) deemed suitable for either approach who had an available single-segment great saphenous vein (GSV). However, the superiority of bypass among those lacking GSV was not established. We aimed to examine comparative treatment outcomes from a real-world CLTI population using the Vascular Quality Initiative-Medicare-linked database. METHODS: We queried the Vascular Quality Initiative-Medicare-linked database for patients with CLTI who underwent first-time lower extremity revascularization (2010-2019). We performed two one-to-one propensity score matchings (PSMs): ET vs bypass with GSV (BWGSV) and ET vs bypass with a prosthetic graft (BWPG). The primary outcome was amputation-free survival. Secondary outcomes were freedom from amputation and overall survival (OS). RESULTS: Three cohorts were queried: BWGSV (N = 5279, 14.7%), BWPG (N = 2778, 7.7%), and ET (N = 27,977, 77.6%). PSM produced two sets of well-matched cohorts: 4705 pairs of ET vs BWGSV and 2583 pairs of ET vs BWPG. In the matched cohorts of ET vs BWGSV, ET was associated with greater hazards of death (hazard ratio [HR] = 1.34, 95% confidence interval [CI], 1.25-1.43; P < .001), amputation (HR = 1.30, 95% CI, 1.17-1.44; P < .001), and amputation/death (HR = 1.32, 95% CI, 1.24-1.40; P < .001) up to 4 years. In the matched cohorts of ET vs BWPG, ET was associated with greater hazards of death up to 2 years (HR = 1.11, 95% CI, 1.00-1.22; P = .042) but not amputation or amputation/death. CONCLUSIONS: In this real-world multi-institutional Medicare-linked PSM analysis, we found that BWGSV is superior to ET in terms of OS, freedom from amputation, and amputation-free survival up to 4 years. Moreover, BWPG was superior to ET in terms of OS up to 2 years. Our study confirms the superiority of BWGSV to ET as observed in the BEST-CLI trial.
引用
- Zarrintan S, Rahgozar S, Ross EG, et al. Endovascular therapy versus bypass for chronic limb-threatening ischemia in a real-world practice. J Vasc Surg. 2024. PMID: 38718850. doi:10.1016/j.jvs.2024.04.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。